146 related articles for article (PubMed ID: 34625562)
1. Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial.
Houvenaeghel G; Cohen M; Raro P; De Troyer J; Gimbergues P; Tunon de Lara C; Ceccato V; Vaini-Cowen V; Faure-Virelizier C; Marchal F; Gauthier T; Jouve E; Theret P; Regis C; Gabelle P; Pernaut J; Del Piano F; D'Halluin G; Lantheaume S; Darai E; Beedassy B; Dhainaut-Speyer C; Martin X; Girard S; Villet R; Monrigal E; Hoyek T; Le Brun JF; Colombo PE; Tallet A; Boher JM;
NPJ Breast Cancer; 2021 Oct; 7(1):133. PubMed ID: 34625562
[TBL] [Abstract][Full Text] [Related]
2. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
Houvenaeghel G; Cohen M; Raro P; De Troyer J; de Lara CT; Gimbergues P; Gauthier T; Faure-Virelizier C; Vaini-Cowen V; Lantheaume S; Regis C; Darai E; Ceccato V; D'Halluin G; Del Piano F; Villet R; Jouve E; Beedassy B; Theret P; Gabelle P; Zinzindohoue C; Opinel P; Marsollier-Ferrer C; Dhainaut-Speyer C; Colombo PE; Lambaudie E; Tallet A; Boher JM;
BMC Cancer; 2018 Nov; 18(1):1153. PubMed ID: 30463611
[TBL] [Abstract][Full Text] [Related]
3. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
4. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
5. The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
Houvenaeghel G; de Nonneville A; Chopin N; Classe JM; Mazouni C; Chauvet MP; Reyal F; Tunon de Lara C; Jouve E; Rouzier R; Daraï E; Gimbergues P; Coutant C; Azuar AS; Villet R; Crochet P; Rua S; Bannier M; Cohen M; Boher JM
Cancer Med; 2023 Feb; 12(4):4023-4032. PubMed ID: 36127853
[TBL] [Abstract][Full Text] [Related]
6. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
7. Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
Majid S; Rydén L; Manjer J
BMC Cancer; 2019 Jun; 19(1):626. PubMed ID: 31238899
[TBL] [Abstract][Full Text] [Related]
8. T-stage and positive sentinel nodes ratio are the useful factors to predict non-sentinel node metastasis in breast cancer patients with macro-metastasis in the sentinel node.
Noda S; Onoda N; Asano Y; Kurata K; Kashiwagi S; Kawajiri H; Takashima T; Hirakawa K
Int J Surg; 2015 Feb; 14():56-60. PubMed ID: 25597234
[TBL] [Abstract][Full Text] [Related]
9. [Sentinel node invasion: is it necessary to perform axillary lymph node dissection? Randomized trial SERC].
Houvenaeghel G; Resbeut M; Boher JM
Bull Cancer; 2014 Apr; 101(4):358-63. PubMed ID: 24793627
[TBL] [Abstract][Full Text] [Related]
10. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
11. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
[TBL] [Abstract][Full Text] [Related]
12. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
13. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
Sávolt A; Polgár C; Musonda P; Mátrai Z; Rényi-Vámos F; Tóth L; Kásler M; Péley G
Clin Breast Cancer; 2013 Oct; 13(5):364-70. PubMed ID: 23773380
[TBL] [Abstract][Full Text] [Related]
14. External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis.
Houvenaeghel G; El Hajj H; Barrou J; Cohen M; Raro P; De Troyer J; Gimbergues P; Tunon de Lara C; Ceccato V; Vaini-Cowen V; Faure-Virelizier C; Marchal F; Gauthier T; Jouve E; Theret P; Regis C; Desmons F; Tallet A; Boher JM;
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050650
[TBL] [Abstract][Full Text] [Related]
15. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
[TBL] [Abstract][Full Text] [Related]
16. Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
Kantor O; Pesce C; Liederbach E; Wang CH; Winchester DJ; Yao K
Breast J; 2017 Sep; 23(5):554-562. PubMed ID: 28295828
[TBL] [Abstract][Full Text] [Related]
17. A Population-Based Study of the Effects of a Regional Guideline for Completion Axillary Lymph Node Dissection on Axillary Surgery in Patients with Breast Cancer.
Tsao MW; Cornacchi SD; Hodgson N; Simunovic M; Thabane L; Cheng J; O'Brien MA; Strang B; Mukherjee SD; Lovrics PJ
Ann Surg Oncol; 2016 Oct; 23(10):3354-64. PubMed ID: 27342830
[TBL] [Abstract][Full Text] [Related]
18. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
19. Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations.
Aigner J; Smetanay K; Hof H; Sinn HP; Sohn C; Schneeweiss A; Marmé F
Ann Surg Oncol; 2013 May; 20(5):1538-44. PubMed ID: 23389469
[TBL] [Abstract][Full Text] [Related]
20. The evolution of the sentinel node procedure in the treatment of breast cancer.
Tvedskov TF
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
